Full-Time

Private Equity Product Specialist

Posted on 10/30/2024

Viking Global

Viking Global

51-200 employees

Compensation Overview

$150k - $200kAnnually

+ Discretionary Bonus

Senior

New York, NY, USA

Category
Private Equity
Finance & Banking
Requirements
  • Excellent communication and interpersonal skills with the ability to articulate thoughts well, both verbally and in writing
  • Prior investor relations or product specialist experience in private equity (preferred). Exposure across multiple products and fund structures is a plus
  • Strong judgment and problem-solving capabilities
  • Teamwork orientation
  • Outstanding attention to detail, organizational skills, focus on process, ability to prioritize multiple projects, and willingness to take ownership of and be accountable for a variety of tasks
  • A strong knowledge of finance and investing
  • An undergraduate degree with a strong academic record
  • Five or more years of experience in a client-oriented investor relations role, investment banking, or consulting
Responsibilities
  • Identifying salient messages for investor communications about investments, the business, the market environment, and competitive positioning. Crafting written and verbal communications on behalf of the firm, including investor letters, presentation materials, speeches, operational due diligence materials, emails, and talking points
  • Serving as liaison between the investor relations client facing team and investment staff
  • Monitoring the competitive landscape and industry dynamics, including through the use of databases
  • Leading cross-functional fund launch and improvement projects
  • Preparing regular updates for the broader firm on investor relations initiatives

Company Size

51-200

Company Stage

N/A

Total Funding

$16.8B

Headquarters

Greenwich, Connecticut

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • Viking's investment in Valsoft highlights growth potential in vertical market software.
  • Their funding in Magenta Medical supports accelerated market entry for innovative heart pumps.
  • Collaboration with AbCellera leverages expertise in antibody drug discovery and development.

What critics are saying

  • Increased competition in heart pumps may impact Magenta Medical's market position.
  • Biotech sector's competitive landscape could challenge new antibody drug programs' success.
  • Multiple funding rounds expose Viking to financial risks if companies underperform.

What makes Viking Global unique

  • Viking Global Investors focuses on vertical market software, a growing and consolidating sector.
  • They invest in innovative medical devices with FDA Breakthrough Device Designation potential.
  • Their collaboration with AbCellera targets early-stage biotech investments in immunology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Performance Bonus

Meal Benefits

Hybrid Work Options

Company News

Yahoo Finance
Dec 26th, 2024
Valsoft Corporation Secures $150M to Further Accelerate Growth in Vertical Market Software Sector

New equity funding from Portage Capital Solutions, Viking Global Investors, and PROPELR Growth underscores Valsoft's leadership and growth potential MONTRÉAL, QC / ACCESSWIRE / December 26, 2024 /Valsoft Corporation Inc. ("Valsoft"), a Canadian company ...

Business Wire
Nov 15th, 2024
Metsera Secures $215 Million Series B Financing to Further Accelerate Portfolio

Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today anno

The Healthcare Technology Report
Aug 19th, 2024
Magenta Medical Raises $105M for Heart Pump

Magenta Medical has secured $105 million in a financing round led by Novo Holdings, with participation from Viking Global Investors, RA Capital Management, and existing investors like OrbiMed and New Enterprise Associates. The funds will support US clinical programs and FDA approval pursuits for the Elevate heart pump, designed for high-risk percutaneous coronary interventions. The Elevate System, noted for its small size and high power, has received Breakthrough Device Designation from the FDA.

The Wall Street Journal
Jul 24th, 2024
Exclusive | Heart-Pump Developer Magenta Medical Raises $105 Million

Israeli startup aims to compete with U.S. heart-pump pioneer Abiomed, now owned by Johnson & Johnson. But analysts say the market has lots of room to grow.

VC News Daily
Jul 19th, 2024
Antheia Secures $17M in New Funding

Antheia announced $17 million in new funding through a government project agreement with the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) and matching support from new strategic investors. The funding includes a non-dilutive two-year project agreement up to $11 million from BioMaP and additional investment from In-Q-Tel, Inc. (IQT), Echo Investment Capital (Echo), and existing investors like Viking Global Investors.

INACTIVE